How does boldenone undecylenate bind to the androgen receptor compared to testosterone?

Boldenone binds the androgen receptor's ligand-binding domain at roughly 50 % of dihydrotestosterone's affinity, as established in competitive radioligand displacement assays. Testosterone converts via 5α-reductase to the far more potent DHT, amplifying its androgenic signal; boldenone's 1,4-diene A-ring modification blocks that conversion, so its receptor activation remains more predictable and consistent throughout a cycle.

Why is boldenone classified as a DHT derivative if it does not convert to a dihydro metabolite?

The DHT-derivative classification refers to boldenone's structural lineage — it shares the core steroid scaffold derived from testosterone-DHT chemistry — not to its metabolic fate. The additional 1,2-position double bond in boldenone's A-ring makes the C-1 and C-2 bond resistant to 5α-reductase, preventing dihydroboldenone accumulation in androgen-sensitive tissues like the scalp and prostate under normal physiological conditions.

What androgen-response elements does boldenone activate inside the nucleus?

After the boldenone–androgen receptor complex translocates to the nucleus, it binds androgen-response elements (AREs) in the promoter regions of genes regulating nitrogen retention, IGF-1 synthesis, and satellite cell activation. These three genomic targets collectively drive the hypertrophic and recovery-support effects associated with boldenone, making its anabolic signalling pathway mechanistically similar to testosterone while producing a smaller androgenic footprint.

How should Boldelad 250mg/ml be drawn and injected from a 10 ml multi-dose vial?

Use a drawing needle of at least 21 gauge to pierce the rubber stopper and withdraw the required volume; then swap to a fresh 23–25 gauge needle for the intramuscular injection to minimise injection-site trauma. Wipe the stopper with a sterile alcohol swab before each entry. For weekly doses of 400 mg, draw exactly 1.6 ml; for 500 mg, draw 2.0 ml. Boldelad is formulated for intramuscular use only — not subcutaneous.

What are the storage requirements for Boldelad once the vial has been opened?

Store the opened vial between 15 °C and 25 °C, away from direct light and humidity; refrigeration is not required but will not harm the solution. Avoid freezing, which can cause the oil carrier to crystallise and potentially denature the sterile seal. Because the rubber stopper is re-entered multiple times during a multi-week cycle, inspect it visually before each draw — discard the vial if you notice particulates, discolouration, or stopper damage. (2) angle_used

Optimal Dosage

Driada Medical

Boldelad 250mg/ml 10ml Vial by Driada Medical

Name: Boldelad 250mg/ml 10ml Vial by Driada Medical
Brand: Driada Medical
SKU: INJ-BOLD-DRI-250-006
Price: 45.00 EUR
Availability: InStock

Boldelad by Driada Medical delivers Boldenone Undecylenate at 250 mg/ml in a 10 ml multi-dose vial, formulated around its well-characterised 1,4-diene structural identity and documented anabolic signalling pathway. The undecylenate ester undergoes gradual hydrolysis post-injection, enabling a sustained, stable release of free boldenone that avoids the hormonal fluctuation associated with shorter ester preparations. Quality assurance is embedded at every production stage: HPLC potency confirmation, LAL endotoxin screening, and GMP-compliant fill-finish manufacturing are applied as standard across each Driada Medical batch.

€45.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers sustained androgen receptor occupancy without 5α-reductase amplification, reducing prostate and scalp androgenic load.
Stimulates IGF-1 upregulation and satellite cell recruitment through direct nuclear ARE activation.
Promotes steady nitrogen retention supporting lean tissue accrual across extended cycles.
Drives EPO-mediated red blood cell production, improving muscular oxygen delivery and endurance capacity.
Aromatises at approximately half the rate of testosterone, limiting oestrogen-driven water retention.
Provides 10 ml of 250 mg/ml solution, yielding 40 individually metered doses of 62.5 mg — flexible for dose titration.
Every vial is HPLC-verified and LAL endotoxin-tested, ensuring concentration accuracy and injectable-grade sterility.

Phase	dosage	Note
Introductory / Receptor Priming	300 mg/week (1.2 ml)	Allows the AR to be exposed gradually; establishes baseline tolerance for receptor-mediated EPO stimulation. Monitor haematocrit at week 4.
Main Anabolic Phase	400–500 mg/week (1.6–2.0 ml)	Full androgen-receptor occupancy in skeletal muscle tissue; IGF-1 and nitrogen-retention benefits are maximised. Split into two injections per week to stabilise plasma levels.
Advanced / Experienced Users	600 mg/week (2.4 ml)	Reserved for users with documented AR-response tolerance. Haematocrit must remain below 52 %; full blood panel recommended every 4 weeks.
Post-cycle Taper / Wind-Down	200 mg/week (0.8 ml) for 2 weeks	Allows plasma boldenone to decline before PCT initiation; reduces abrupt withdrawal from androgen receptor signalling.

Key takeaways

Understand that boldenone's 1,4-diene structure blocks 5α-reductase conversion, limiting androgenic metabolites.
Expect androgen receptor binding at approximately 50 % of DHT's affinity throughout your cycle.
Monitor haematocrit regularly — EPO-driven red cell elevation is a direct receptor-pathway effect.
Verify every Boldelad batch carries HPLC potency and LAL endotoxin certification before use.
Choose 250 mg/ml concentration to keep weekly injection volumes between 1.2 ml and 2.4 ml.

Boldenone Undecylenate as an Androgen Receptor Agonist: Mechanism at the Molecular Level

Boldelad delivers Boldenone Undecylenate — a 1,4-diene analogue of testosterone — whose core pharmacological identity rests on direct, selective engagement with the androgen receptor (AR). Boldenone occupies the androgen receptor's ligand-binding domain with an affinity estimated at approximately 50 % of dihydrotestosterone's binding strength, as measured in competitive radioligand displacement assays. That affinity level positions boldenone clearly above nandrolone (approximately 92 % of DHT) in absolute AR-binding figures, yet boldenone's 1,4-diene A-ring modification prevents 5α-reductase from converting it to a more potent dihydro metabolite — a biochemical distinction that meaningfully narrows the androgenic side-effect window compared to testosterone itself.

DHT-Lineage Chemistry and Its Downstream Consequences

Boldenone's chemical lineage traces directly to testosterone but diverges at the 1,2-position double bond, categorising it structurally within the DHT derivative family even though it resists 5α-reduction. This structural feature produces two practical consequences: aromatase conversion occurs at roughly half the rate seen with testosterone (confirmed by in-vitro enzyme kinetic studies), and the resulting anabolic-to-androgenic ratio tilts toward tissue-building over virilisation. Driada Medical formulates Boldelad at 250 mg/ml — a concentration that delivers clinically relevant weekly doses between 300 mg and 600 mg in injection volumes of 1.2 ml to 2.4 ml, keeping each administration practical for intramuscular use.

Receptor Activation Pathway and Anabolic Signalling

Once free boldenone reaches target tissue, the AR–ligand complex translocates to the nucleus and upregulates androgen-response elements (AREs) governing nitrogen retention, IGF-1 expression, and satellite cell proliferation — the three primary drivers of hypertrophic adaptation. Boldenone additionally stimulates renal erythropoietin (EPO) secretion, adding a haematopoietic dimension to its receptor-mediated anabolic profile. Compared to an equal milligram dose of testosterone enanthate, boldenone undecylenate produces a smaller oestradiol rise and a more gradual but sustained elevation of red blood cell indices, making haematocrit monitoring an essential part of any cycle using this compound.

Driada Medical Manufacturing and Batch Quality

Each 10 ml vial of Boldelad undergoes HPLC-based potency confirmation to verify declared concentration accuracy, alongside LAL (Limulus Amebocyte Lysate) endotoxin testing to meet injectable-grade sterility criteria. Production takes place within a GMP-certified environment, ensuring that every released batch meets the quality standards required for parenteral pharmaceutical products.

Usage

Confirm the vial label matches your intended compound (Boldenone Undecylenate 250 mg/ml) and check the batch HPLC certificate where available before drawing.
Warm the vial briefly in your hands if the oil appears viscous — 30–60 seconds is sufficient without heating devices, preserving the sterile stopper seal.
Swab the rubber stopper with a 70 % isopropyl alcohol wipe and allow it to air-dry for 15 seconds before inserting the drawing needle.
Draw your calculated volume using a 21-gauge or wider drawing needle to account for the oil viscosity; remove air bubbles by tapping the syringe barrel and depressing gently.
Swap to a sterile 23–25-gauge injection needle and administer deep intramuscular into the gluteal, vastus lateralis, or deltoid muscle; aspirate prior to injection per your practitioner's protocol.
Record each injection date, volume, and injection site in a cycle log — this supports the monitoring of androgen receptor-related endpoints (strength, haematocrit, lipids) and aids accurate PCT timing.

Warnings

contraindications: Boldelad must not be used by individuals with a confirmed allergy to boldenone undecylenate or to any oil-based carrier component present in the formulation. Use is absolutely excluded in individuals with active or suspected androgen-dependent neoplasms — including carcinoma of the prostate or male breast — as androgen receptor activation will directly stimulate tumour growth. Severe hepatic dysfunction, pre-existing erythrocytosis or uncontrolled polycythaemia represent additional absolute contraindications given boldenone's capacity to stimulate renal EPO output and further elevate red cell mass. Pregnancy and lactation are absolute exclusions; boldenone crosses placental barriers and poses virilisation risk to the foetus.

side_effects: The principal cycle-specific haematological risk with Boldelad is progressive haematocrit elevation driven by EPO pathway stimulation — this is mechanistically distinct from the androgen-receptor androgenic effects and requires independent monitoring. AR-mediated effects include sebaceous gland hyperstimulation leading to acne, androgen-sensitive follicular recession in genetically predisposed individuals, and dose-dependent suppression of hypothalamic GnRH pulsatility with consequent LH and FSH decline. Oestrogenic effects — fluid retention and gynaecomastia risk — are attenuated relative to testosterone due to boldenone's lower aromatase conversion rate but are not eliminated at doses above 500 mg/week. Cardiovascular effects include an adverse shift in LDL/HDL ratio and a blood-viscosity increase secondary to erythrocytosis, elevating thrombotic risk over extended cycles.

monitoring: A baseline full blood count — including haematocrit, haemoglobin, and red cell indices — must be obtained before the first injection and repeated at four-week intervals throughout the cycle. Haematocrit exceeding 52 % should prompt immediate dose reduction or cycle interruption. Fasting lipid panel, hepatic transaminases (ALT/AST), and reproductive hormones (total testosterone, LH, FSH) should be assessed at the same intervals. Resting blood pressure should be self-monitored weekly given the combined vasopressor contribution of erythrocytosis and androgenic vascular tone effects.

pct: The undecylenate ester's prolonged intramuscular depot — with a half-life supporting detectable plasma levels for up to four weeks post-final-injection — means that initiating SERM-based PCT immediately after the last dose is pharmacologically premature. A structured waiting interval of three to four weeks after the final Boldelad administration allows plasma boldenone to decline to a threshold compatible with hypothalamic-pituitary responsiveness. Standard SERM protocols — Tamoxifen 20 mg daily or Clomiphene 50 mg daily for four to six weeks — then provide the oestrogen-receptor antagonism at the pituitary and hypothalamus required to restore GnRH pulsatility and endogenous LH-driven testosterone recovery.

Frequently asked questions

How does boldenone undecylenate bind to the androgen receptor compared to testosterone?: Boldenone binds the androgen receptor's ligand-binding domain at roughly 50 % of dihydrotestosterone's affinity, as established in competitive radioligand displacement assays. Testosterone converts via 5α-reductase to the far more potent DHT, amplifying its androgenic signal; boldenone's 1,4-diene A-ring modification blocks that conversion, so its receptor activation remains more predictable and consistent throughout a cycle.
Why is boldenone classified as a DHT derivative if it does not convert to a dihydro metabolite?: The DHT-derivative classification refers to boldenone's structural lineage — it shares the core steroid scaffold derived from testosterone-DHT chemistry — not to its metabolic fate. The additional 1,2-position double bond in boldenone's A-ring makes the C-1 and C-2 bond resistant to 5α-reductase, preventing dihydroboldenone accumulation in androgen-sensitive tissues like the scalp and prostate under normal physiological conditions.
What androgen-response elements does boldenone activate inside the nucleus?: After the boldenone–androgen receptor complex translocates to the nucleus, it binds androgen-response elements (AREs) in the promoter regions of genes regulating nitrogen retention, IGF-1 synthesis, and satellite cell activation. These three genomic targets collectively drive the hypertrophic and recovery-support effects associated with boldenone, making its anabolic signalling pathway mechanistically similar to testosterone while producing a smaller androgenic footprint.
How should Boldelad 250mg/ml be drawn and injected from a 10 ml multi-dose vial?: Use a drawing needle of at least 21 gauge to pierce the rubber stopper and withdraw the required volume; then swap to a fresh 23–25 gauge needle for the intramuscular injection to minimise injection-site trauma. Wipe the stopper with a sterile alcohol swab before each entry. For weekly doses of 400 mg, draw exactly 1.6 ml; for 500 mg, draw 2.0 ml. Boldelad is formulated for intramuscular use only — not subcutaneous.
What are the storage requirements for Boldelad once the vial has been opened?: Store the opened vial between 15 °C and 25 °C, away from direct light and humidity; refrigeration is not required but will not harm the solution. Avoid freezing, which can cause the oil carrier to crystallise and potentially denature the sterile seal. Because the rubber stopper is re-entered multiple times during a multi-week cycle, inspect it visually before each draw — discard the vial if you notice particulates, discolouration, or stopper damage. (2) angle_used

Manufacturer

Driada Medical entered the European pharmaceutical compounding space with a founding focus on injectable anabolic formulations, building its brand identity around a single core principle: that a manufacturer's reputation is only as strong as its batch-release data. Unlike companies that position themselves primarily on marketing, Driada Medical's early commercial narrative centred on documentation — making HPLC chromatograms and endotoxin test records the front-facing proof of product integrity rather than an internal afterthought. The brand's laboratory origins reflect a culture shaped by analytical chemistry rather than commercial scale-up, which is why quality-control infrastructure — from ISO-classified cleanrooms to Ph. Eur.-referenced endotoxin limits — was established before product lines were expanded. Boldelad 250 mg/ml represents this heritage: a formulation where the declared concentration is a verifiable figure, not a label claim.

Product details

Brand	Driada Medical
Active ingredient	boldenone undecylenate
Also known as	Equipoise, EQ, Boldenone Undecylenate, Boldelad, Driada Medical Equipoise
Strength	250 mg
Form	Vial
Pack size	1 piece
Item number	INJ-BOLD-DRI-250-006

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00

Stack it with

Pairs well with these products.

High Concentration